在P53-突变子宫内膜癌中,IL4I1作为治疗点的蛋白质识别
Hu Li1, Ruonan Zhang2, Tiantian Sui1
1Shanghai Key Laboratory of Maternal Fetal Medicine, Shanghai Institute of Maternal-Fetal Medicine and Gynecologic Oncology, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, Shanghai 200092, China.
Cancers
|September 27, 2025
概括
在具有TP53突变的高风险子宫内膜癌 (EC) 中,介素-4诱导的1 (IL4I1) 被上调调节. 准IL4I1可能为这种侵袭性癌症亚型提供新的治疗策略.
科学领域:
- 妇科瘤学 妇科瘤学
- 癌症基因组学 癌症基因组学
- 免疫学 免疫学 免疫学
背景情况:
- 在全球范围内,子宫内膜癌 (EC) 发病率正在上升.
- 癌症基因组图谱 (TCGA) 将EC分为四种分子亚型,TP53-突变EC的预后不佳.
- 一种免疫调节酶IL4I1是瘤进展的潜在生物标志物.
研究的目的:
- 研究IL4I1作为TP53-突变子宫内膜癌的预后标志物.
- 评估IL4I1作为高风险EC的潜在治疗点.
主要方法:
- 对495名EC患者的回顾性分析,其中33例TP53突变病例被选择.
- 通过蛋白质组学,免疫组织化学和西式涂抹评估IL4I1表达.
- 使用IL4I1-Knockout细胞系和异种移植模型的功能研究.
主要成果:
- 已故患者的IL4I1显著上调,并与免疫微环境变化有关.
- 在试验室中,IL4I1淘汰抑制了增殖,迁移和入侵.
- 在体内,IL4I1淘汰赛抑制了瘤生长.
结论:
- IL4I1在TP53突变EC的攻击性中起着至关重要的作用.
- IL4I1显示出作为高风险EC的预后生物标志物的潜力.
- 在这种EC亚型中,IL4I1代表了精密医学的新型治疗标.
相关概念视频
02:23Abnormal Proliferation
5.1K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K